Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label Phase 2 Study of Oral BCX9930 in C3 Glomerulopathy, IgA Nephropathy, or Primary Membranous Nephropathy
2020-005855-19Phase 2Terminated
- Sponsor
- BioCryst Pharmaceuticals, Inc.
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vimircopan in Complement 3 glomerulopathy (C3G), IgA nephropathy (IgAN) and idiopathic membranous glomerulonephritis (IMG), sponsored by BioCryst Pharmaceuticals, Inc. Primary endpoint: Change in uPCR from baseline. Started Aug 2021; status: terminated.
02
Drugs
vimircopan
03
Conditions
Complement 3 glomerulopathy (C3G)IgA nephropathy (IgAN)idiopathic membranous glomerulonephritis (IMG)
Beyond the preview
Go deeper on 2020-005855-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005855-19.